Faron Pharmaceuticals has announced that it will present Phase 1/2 data from its ongoing BEXMAB study at the 65th American Society of Hematology (ASH) Annual Meeting. The study is investigating the use of bexmarilimab in combination with standard of care (SoC) in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients who have failed hypomethylating agents. The poster presentation will contain updated clinical data from the study. The ASH Annual Meeting will take place from December 9-12, 2023, in San Diego, California and virtually. The lead authors of the study are Dr. Mika Kontro, MD, PhD, Associate Professor at the University of Helsinki, and Dr. Naval Daver, MD, Associate Professor of Leukemia at The University of Texas MD Anderson Cancer Center.

The BEXMAB study is an open-label Phase 1/2 clinical trial investigating bexmarilimab in combination with SoC in the aggressive hematological malignancies of AML and MDS. The primary objective of the study is to determine the safety and tolerability of bexmarilimab in combination with SoC treatment and to identify the recommended Phase II dose. Bexmarilimab is Faron's investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes by targeting myeloid cell function and igniting the immune system. It binds to Clever-1, an immunosuppressive receptor found on macrophages, and alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive state to an immunostimulatory one, priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies. Its lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody being investigated in Phase 1/2 clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.